Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | CHIEF LEGAL OFFICER, SECRETARY | February 03, 2026 | February 05, 2026 |
| Korro Bio, Inc.FREQ · Entity 6388 | General Counsel and Secretary | April 20, 2021 | April 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2036-02-03 | Direct | 176,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 176,000 · Balance 176,000 F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.
Korro Bio, Inc.
Report date April 20, 2021 · Filed April 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 30,000 |
Reported balance
After 2021-04-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 13:44 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 176,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000034 · wk-form4_1770299088.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Underlying: Class A Common Stock · 176,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 12:52 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,020 | $6.83 | $6,966.50 |
DisclosureSEC source: 0001790340-25-000121 · wk-form4_1759409561.xml · nonDerivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,870 Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:06 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 110,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000022 · wk-form4_1738962402.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 93,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 8 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Class A Common Stock · 93,000 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 93,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 7 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 93,000 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 143,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 6 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 143,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 5 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 143,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 47,300 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 4 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,300 Underlying: Class A Common Stock · 47,300 shares Expires 2032-02-09 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 47,300 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 3 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 47,300 shares Expires 2032-02-09 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 101,116 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 2 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,116 Underlying: Class A Common Stock · 101,116 shares Expires 2031-07-28 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on July 15, 2022 and then in equal monthly installments over the subsequent three years, subject to Mr. Bookman's continued employment through each applicable vesting date. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:20 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 101,116 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001628280-24-024953 · wk-form4_1716495592.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 101,116 shares Expires 2031-07-28 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on July 15, 2022 and then in equal monthly installments over the subsequent three years, subject to Mr. Bookman's continued employment through each applicable vesting date. F1 · balance_after: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:14 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 1,448 | $1.62 | $2,345.76 |
DisclosureSEC source: 0001790340-24-000032 · wk-form4_1710890058.xml · nonDerivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,850 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:17 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 93,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000010 · wk-form4_1707513430.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · CHIEF LEGAL OFFICER, SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,000 Underlying: Class A Common Stock · 93,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 143,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002755 · form4-02172023_040202.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Class A Common Stock · 143,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 17, 2022 Filed May 18, 2022 23:28 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,000 | $4.88 | $4,880.00 |
DisclosureSEC source: 0001415889-22-005253 · form4-05182022_040523.xml · nonDerivative · entry 1 Bookman Michael · CIK 0001840339 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,402 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 22:29 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 47,300 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001325 · form4-02142022_020236.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · GENERAL COUNSEL AND SECRETARY 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,300 Underlying: Class A Common Stock · 47,300 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,402 | $15.00 | $21,030.00 |
DisclosureSEC source: 0001104659-21-099728 · tm2123807-4_4seq1.xml · nonDerivative · entry 1 Bookman Michael · CIK 0001840339 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,402 Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:29 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 101,116 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-21-098276 · tm2123556-11_4seq1.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,116 Underlying: Class A Common Stock · 101,116 shares Expires 2031-07-28 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on July 15, 2022 and then in equal monthly installments over the subsequent three years, subject to Mr. Bookman's continued employment through each applicable vesting date. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 20:11 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantRestricted Stock Unit · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014276 · form4.xml · derivative · entry 1 Bookman Michael · CIK 0001840339 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest as to 50% on February 14, 2022 and 50% on July 4, 2022. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.